Cassava Sciences Inc (SAVA)

NASDAQ
41.43
-0.36(-0.86%)
After Hours
41.43
0.00(0.00%)
- Real-time Data
  • Volume:
    586,873
  • Bid/Ask:
    41.25/41.43
  • Day's Range:
    40.83 - 43.18

SAVA Overview

Prev. Close
41.79
Day's Range
40.83 - 43.18
Revenue
-
Open
41.68
52 wk Range
1.63 - 117.5
EPS
-0.28
Volume
586,873
Market Cap
1.66B
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
3,181,645
P/E Ratio
-
Beta
1.14
1-Year Change
430.47%
Shares Outstanding
40,008,654
Next Earnings Date
Aug 17, 2021
What is your sentiment on Cassava Sciences Inc?
or
Market is currently closed. Voting is open during market hours.

Cassava Sciences Inc News

Cassava Sciences Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellStrong SellNeutralStrong Buy
Technical IndicatorsStrong BuyStrong SellSellBuyStrong Buy
SummaryBuyStrong SellStrong SellNeutralStrong Buy

Cassava Sciences Inc Company Profile

Cassava Sciences Inc Company Profile

Employees
11

Cassava Sciences, Inc., formerly Pain Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing drug for the treatment of nervous system disorders. The Company is ocused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer’s. Its drug candidate, PTI-125, is a small molecule that targets an altered form of a scaffolding protein called filamin A (FLNA). The Company is also developing an experimental biomarker/diagnostic, PTI-125Dx. It is developing PTI-125Dx to detect Alzheimer’s disease with a blood test.

Read More
  • https://www.forbes.com/sites/greatspeculations/2021/03/19/can-rally-in-cassava-sciences-stock-continue/?sh=c7eef40855cb
    0
    • I think HFs are betting on the unsuccessful third phase of tests At this stage it is a coin flip, don’t you?
      0
      • ABCD pattern - should move upside
        0
        • ??
          0
          • https://seekingalpha.com/article/4411393-cassava-sciences-early-to-alzheimers-market
            0
            • Price target is increased to $97. Check the link below.
              0
              • https://finance.yahoo.com/news/cassava-alzheimer-treatment-progress-merits-230101795.html
                0
                • this could come down to 25 or even much lower if the market crash would start kicking in big time.
                  2
                  • https://finance.yahoo.com/news/cassava-sciences-announces-positive-end-133000001.html
                    0
                    • Good news from fda out. Wait for sava to partner with big pharma company in the coming weeks
                      0
                      • Source, please? Cheers.
                        0
                    • option expiration Friday is over and the option pupers will move on
                      0
                      • 🚀🚀🚀🚀🚀🚀🚀
                        0
                        • heading down again
                          0
                          • Cassava Sciences price target raised to $66 from $20 at H.C. Wainwright 06:14 SAVA H.C. Wainwright analyst Vernon Bernardino raised the firm's price target on Cassava Sciences to $66 from $20 and reiterates a Buy rating on the shares. The positive interim analysis from an open-label clinical trial with simufilam for Alzheimer's disease raise potential for signing a "lucrative" deal in 2021, Bernardino tells investors in a research note. The analyst beileves simufilam's target, altered FLNA, represents a scarcity in Alzheimer's drug development. Read more at: https://thefly.com/n.php?id=3247487
                            3
                            • this might be a buy in Tuesday
                              4
                              • has came down over 50% since I sold
                                1
                              • still not a buy
                                1
                            • FDA approval next week will send this skyrocketing!🚀🚀🚀🚀🚀🚀🚀
                              0
                              • Is this confirm?
                                0
                            • its a dog to 23.53 to fill the gap
                              0
                              • Cassava Sciences to offer $200 million of shares priced at $49 each vs. $57.56 at Tuesday's close MarketWatch
                                0
                                • Why is it dropping so much?
                                  0
                                  • What's the prediction? Buy or sell?
                                    0
                                    • FDA minutes due out on or about Feb. 14th.  what they say will certainly guide the price of SAVA.
                                      0
                                    • omar omarhttps://www.marketwatch.com/story/pain-therapeutics-stock-plunges-after-company-slams-fda-for-refusing-to-approve-drug-2019-02-05
                                      0
                                  • i dont understand why ist going so down
                                    1
                                    • no guys. it is down because they just announced 200M$ sells offering
                                      0
                                    • omar omar Totally agree... normally I never average in, but in this case I do. Patience until Summer
                                      0
                                    • Andrea Selig FDA minutes will be out on or about Feb 14.  We will know more by then
                                      0
                                  • Sell
                                    3
                                    • it's going to the moon
                                      0
                                      • Wait for approval. Let profit takers take them, if they need to.
                                        1
                                        • when is the approval
                                          0
                                      • *******:(
                                        0
                                        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.